Cholesterol management in US adults with ASCVD in the Family Heart Database® during 2022-23: Current state of care and opportunities for improvement.

ABSTRACT:

Background

Adults with atherosclerotic cardiovascular disease (ASCVD) have increased risk of recurrent events and need optimized low density lipoprotein-cholesterol (LDL-C) lowering therapy, yet the factors contributing to LDL-C management are not well understood.

Methods

This cohort study of the national Family Heart Database aims to characterize the current state of LDL-C management in US adults with ASCVD. Adults with ASCVD and ≥1 medication claim yearly and ≥1 LDL-C measure during 2022 or 2023 were included. The lowest LDL-C level reported (<55 mg/dL; 55-69 mg/dL; ≥70 mg/dL); intensity of dispensed LDL-C therapy (high intensity; low/moderate intensity; none); and duration of dispensed LDL-C therapy (>20 of 24 months; 13 to 20 months; >0 to <13 months; none) were characte

SUBMITTER: MacDougall DE 

PROVIDER: S-EPMC12723117 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature